Free Trial

Applied Dna Sciences (BNBX) Competitors

Applied Dna Sciences logo
$0.09 0.00 (0.00%)
As of 11/13/2026 11:30 AM Eastern

BNBX vs. BRTX, HCWB, ONCO, APVO, and ENLV

Should you buy Applied Dna Sciences stock or one of its competitors? Applied Dna Sciences's main competitors and comparable companies include Biorestorative Therapies (BRTX), HCW Biologics (HCWB), Onconetix (ONCO), Aptevo Therapeutics (APVO), and Enlivex Therapeutics (ENLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Applied Dna Sciences compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Applied Dna Sciences (NASDAQ:BNBX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Biorestorative Therapies has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Applied Dna Sciences has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Applied Dna Sciences has a net margin of -1,647.25% compared to Biorestorative Therapies' net margin of -3,088.27%. Applied Dna Sciences' return on equity of -349.95% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,088.27% -508.42% -230.94%
Applied Dna Sciences -1,647.25%-349.95%-283.96%

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 22.2% of Applied Dna Sciences shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 6.1% of Applied Dna Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Applied Dna Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Biorestorative Therapies has higher earnings, but lower revenue than Applied Dna Sciences. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Applied Dna Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$360K5.71-$14.24M-$21.40N/A
Applied Dna Sciences$2.09M0.27-$15.16M-$3.33N/A

In the previous week, Biorestorative Therapies had 4 more articles in the media than Applied Dna Sciences. MarketBeat recorded 4 mentions for Biorestorative Therapies and 0 mentions for Applied Dna Sciences. Biorestorative Therapies' average media sentiment score of 0.21 beat Applied Dna Sciences' score of 0.00 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company Overall Sentiment
Biorestorative Therapies Neutral
Applied Dna Sciences Neutral

Summary

Biorestorative Therapies beats Applied Dna Sciences on 9 of the 14 factors compared between the two stocks.

How does Applied Dna Sciences compare to HCW Biologics?

Applied Dna Sciences (NASDAQ:BNBX) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

In the previous week, HCW Biologics had 2 more articles in the media than Applied Dna Sciences. MarketBeat recorded 2 mentions for HCW Biologics and 0 mentions for Applied Dna Sciences. HCW Biologics' average media sentiment score of 0.89 beat Applied Dna Sciences' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Dna Sciences Neutral
HCW Biologics Positive

Applied Dna Sciences has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

22.2% of Applied Dna Sciences shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 6.1% of Applied Dna Sciences shares are owned by company insiders. Comparatively, 9.1% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

HCW Biologics has lower revenue, but higher earnings than Applied Dna Sciences. HCW Biologics is trading at a lower price-to-earnings ratio than Applied Dna Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Dna Sciences$2.09M0.27-$15.16M-$3.33N/A
HCW Biologics$50K34.63-$7.96M-$27.60N/A

HCW Biologics has a net margin of -83.03% compared to Applied Dna Sciences' net margin of -1,647.25%. HCW Biologics' return on equity of -262.33% beat Applied Dna Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied Dna Sciences-1,647.25% -349.95% -283.96%
HCW Biologics -83.03%-262.33%-34.90%

HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 3,780.48%. Given HCW Biologics' stronger consensus rating and higher possible upside, analysts clearly believe HCW Biologics is more favorable than Applied Dna Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Dna Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
HCW Biologics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

HCW Biologics beats Applied Dna Sciences on 12 of the 16 factors compared between the two stocks.

How does Applied Dna Sciences compare to Onconetix?

Applied Dna Sciences (NASDAQ:BNBX) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Dna Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Onconetix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Onconetix has lower revenue, but higher earnings than Applied Dna Sciences. Applied Dna Sciences is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Dna Sciences$2.09M0.27-$15.16M-$3.33N/A
Onconetix$810K2.34-$14.03M$2.48 thousand0.00

22.2% of Applied Dna Sciences shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 6.1% of Applied Dna Sciences shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Onconetix has a net margin of -1,575.89% compared to Applied Dna Sciences' net margin of -1,647.25%. Onconetix's return on equity of -91.95% beat Applied Dna Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied Dna Sciences-1,647.25% -349.95% -283.96%
Onconetix -1,575.89%-91.95%-53.76%

Applied Dna Sciences has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.62, suggesting that its share price is 162% more volatile than the broader market.

In the previous week, Onconetix had 6 more articles in the media than Applied Dna Sciences. MarketBeat recorded 6 mentions for Onconetix and 0 mentions for Applied Dna Sciences. Onconetix's average media sentiment score of 0.13 beat Applied Dna Sciences' score of 0.00 indicating that Onconetix is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Dna Sciences Neutral
Onconetix Neutral

Summary

Onconetix beats Applied Dna Sciences on 11 of the 13 factors compared between the two stocks.

How does Applied Dna Sciences compare to Aptevo Therapeutics?

Applied Dna Sciences (NASDAQ:BNBX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Applied Dna Sciences has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Aptevo Therapeutics has a net margin of 0.00% compared to Applied Dna Sciences' net margin of -1,647.25%. Aptevo Therapeutics' return on equity of -201.49% beat Applied Dna Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied Dna Sciences-1,647.25% -349.95% -283.96%
Aptevo Therapeutics N/A -201.49%-119.21%

In the previous week, Aptevo Therapeutics had 6 more articles in the media than Applied Dna Sciences. MarketBeat recorded 6 mentions for Aptevo Therapeutics and 0 mentions for Applied Dna Sciences. Applied Dna Sciences' average media sentiment score of 0.00 beat Aptevo Therapeutics' score of -0.04 indicating that Applied Dna Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Applied Dna Sciences Neutral
Aptevo Therapeutics Neutral

Applied Dna Sciences has higher revenue and earnings than Aptevo Therapeutics. Applied Dna Sciences is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Dna Sciences$2.09M0.27-$15.16M-$3.33N/A
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A

22.2% of Applied Dna Sciences shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 6.1% of Applied Dna Sciences shares are owned by company insiders. Comparatively, 0.4% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Dna Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Applied Dna Sciences and Aptevo Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Applied Dna Sciences compare to Enlivex Therapeutics?

Applied Dna Sciences (NASDAQ:BNBX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

22.2% of Applied Dna Sciences shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 6.1% of Applied Dna Sciences shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Applied Dna Sciences has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Enlivex Therapeutics has a consensus target price of $4,800.00, suggesting a potential upside of 403,261.34%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Applied Dna Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Dna Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Enlivex Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Enlivex Therapeutics has a net margin of 0.00% compared to Applied Dna Sciences' net margin of -1,647.25%. Enlivex Therapeutics' return on equity of 0.00% beat Applied Dna Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied Dna Sciences-1,647.25% -349.95% -283.96%
Enlivex Therapeutics N/A N/A N/A

In the previous week, Enlivex Therapeutics had 2 more articles in the media than Applied Dna Sciences. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 0 mentions for Applied Dna Sciences. Enlivex Therapeutics' average media sentiment score of 1.41 beat Applied Dna Sciences' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Dna Sciences Neutral
Enlivex Therapeutics Positive

Enlivex Therapeutics has lower revenue, but higher earnings than Applied Dna Sciences. Applied Dna Sciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Dna Sciences$2.09M0.27-$15.16M-$3.33N/A
Enlivex TherapeuticsN/AN/A$1.24B-$131.93N/A

Summary

Enlivex Therapeutics beats Applied Dna Sciences on 12 of the 15 factors compared between the two stocks.

Get Applied Dna Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for BNBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNBX vs. The Competition

MetricApplied Dna SciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$558K$4.13B$7.89B$12.08B
Dividend YieldN/A3.64%2.47%4.53%
P/E Ratio-0.0324.6434.5930.65
Price / Sales0.2716.298.665.81
Price / CashN/A21.8921.0222.32
Price / Book0.064.504.803.95
Net Income-$15.16M-$24.19M$3.52B$391.64M
7 Day PerformanceN/A-4.44%-3.20%-2.48%
1 Month PerformanceN/A-2.06%-1.47%-3.98%
1 Year PerformanceN/A-1.72%1.46%-5.71%

Applied Dna Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNBX
Applied Dna Sciences
N/A$0.09
flat
N/AN/A$558K$2.09MN/A70
BRTX
Biorestorative Therapies
1.0149 of 5 stars
$1.56
+2.0%
N/A-94.4%$2.11M$360KN/A14
HCWB
HCW Biologics
2.3293 of 5 stars
$0.86
-8.5%
$30.00
+3,388.4%
-95.7%$2.10M$50KN/A35
ONCO
Onconetix
0.6816 of 5 stars
$3.76
+8.4%
N/A-99.7%$2.04M$810KN/A2
APVO
Aptevo Therapeutics
1.0181 of 5 stars
$0.76
-29.6%
N/A-97.7%$1.96MN/AN/A33

Related Companies and Tools


This page (NASDAQ:BNBX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners